# PT-141 Mechanism of Action: MC4R Agonism in the Brain > PT-141 mechanism of action, receptor by receptor: MC4R/MC3R agonism in hypothalamic circuits, dopaminergic desire signaling, and the MC1R skin effect. Cited, lab-notebook detail. MC4R primary, MC3R secondary, MC1R peripheral. Hypothalamic circuits, dopaminergic desire signaling, and the c-Fos and fMRI evidence — receptor by receptor. ## Before the details The PT-141 mechanism of action is, in one line: it switches on melanocortin receptors in the brain — mainly the MC4R type — and that drives sexual desire [1][5]. This page goes receptor by receptor and circuit by circuit, but the through-line stays simple. MC4R (the main target) sits in hypothalamic circuits that set sexual motivation. Switch it on, and a desire signal involving dopamine — a brain chemical tied to wanting — is engaged [5][11]. MC3R is a secondary brain target in the same direction [1]. MC1R is a different story: it lives in the skin, and switching it on explains the skin-darkening seen with frequent dosing [7]. The action is central; the peptide does not work on blood vessels [10]. The hard evidence is animal neuron-firing data (c-Fos) and human brain imaging (fMRI), both below. ## The primary target: MC4R in hypothalamic circuits PT-141's primary mechanism is MC4R agonism in the brain. MC4R is concentrated in the hypothalamus and limbic system — including the medial preoptic area, a hub for sexual motivation [1]. Activating MC4R there is thought to engage dopaminergic pathways that govern desire and arousal [5][11]. The defining contrast: unlike PDE-5 inhibitors, which act peripherally on vascular smooth muscle, PT-141 works centrally, on the neural circuitry of sexual motivation [10]. The peptide is a synthetic cyclic heptapeptide that activates central melanocortin receptors, chiefly MC4R, with MC3R as a secondary central pathway [1]. This receptor selectivity — central MC4R/MC3R over peripheral targets — is what makes it a desire drug rather than a blood-flow drug. ## The evidence the mechanism is central Two lines of direct evidence anchor the central mechanism. First, animal pharmacology: systemic PT-141 activated hypothalamic neurons measured as increased c-Fos (a protein that rises when neurons fire), in parallel with dose-dependent erectile activity in rats and primates — the brain was firing, not just the periphery [1]. In female rats, the peptide selectively raised appetitive solicitational behavior without changing reflexive or motor behavior — a desire-specific central effect [2]. Second, human neuroimaging: in 31 premenopausal women with HSDD, MC4R agonism increased desire for up to 24 hours and altered task-based brain processing of erotic stimuli, enhancing amygdala-insula functional connectivity and changing cerebellar/supplementary-motor activity [5]. A 2025 hamster study refined the picture — the peptide did not enhance sexual *reward* via the VTA-NAc circuit, locating its action in desire rather than reward [6]. ## Secondary receptors: MC3R and the peripheral MC1R MC3R is the secondary central target, agonized alongside MC4R and contributing to the central melanocortin signal [1]. The melanocortin system more broadly is a leading therapeutic target for metabolic disorders, and bremelanotide's approval helped demonstrate the safety of this receptor class [8]. MC1R is the peripheral outlier. It sits in skin melanocytes, and PT-141's activation of it is the mechanism behind hyperpigmentation — darkening of face, gums, and breasts — reported with repeated frequent dosing [7]. MC4R's presence in appetite circuits is a second off-target route: it underlies the caloric-intake and body-weight effects seen in high-frequency Phase 1 research dosing, a pharmacological consideration rather than an approved use [9]. One peptide, several receptors, one dominant central effect — and a few peripheral consequences that follow from the receptor map. --- A two-ink lab-notebook digest of the PT-141 (bremelanotide) record — the central MC4R mechanism, the premenopausal-HSDD-only approval, and the nausea-led tolerability cost logged to source and overprinted in plain sight, with the research-chemical form kept clearly off-register from the approved drug; no clinic behind the press and nothing here dosed, dispensed, or sold.